Printer Friendly

Enzyme study suggests anti-AIDS strategy.

Biochemists working to understand HIV infection may have found a way to slow or stop replication of the AIDS virus before it really starts.

A research team from the National Cancer Institute (NCI) in Bethesda, Md., and Temple University of Philadelphia has pinpointed the site where a key HIV enzyme latches onto RNA belonging to the infected cell. In the Nov. 12 BIOCHEMISTRY, the group also reports creating small molecules that can settle into this site. These molecules may represent a first step toward developing therapeutic compounds that can prevent the virus from co-opting a cell, says Samuel H. Wilson, who codirected the NCI work with Dolph L. Hatfield.

"[The new results] will provide us with the information necessary to design compounds that can block or interfere with the actions of the enzyme," says Wilson, who is now at the University of Texas Medical Branch at Galveston.

"It might represent a new mechanism of inhibiting the [enzyme known as] reverse transcriptase, and any novel mechanism is important," comments David K. Stammers, a biochemist with Wellcom Research in Beckenham, England. Zidovudine (AZT) also affects reverse transcriptase, but in a different way.

Indeed, according to Robert J. Suhadolnik, who led the Temple University contingent, the group has made specific binding inhibitors for reverse transcriptase. Suhadolnik and colleagues from Germany and France reported promising results from such a compound in the Feb. 26 BIOCHEMISTRY. "[Such inhibitors] could either complement AZT or lower the concentration of AZT needed, [so that one could] get away from the toxic effects," he says. "Our goal right now is to find a method by which this could be delivered into the human cell without damaging the cell."

Reverse transcriptase enables the virus to run the infected cell's genetic machinery in reverse. Usually, the coding of a cell's DNA provides instructions to RNA, which then arranges amino acids into specific proteins. HIV uses reverse transcriptase to get RNA to instead create new DNA coding that includes the virus' genetic information.

The enzyme binds to one part of a specific piece of host transfer RNA, so called because it transports amino acids for protein synthesis. To locate this binding site, the NCI-Temple group first made probes -- molecules resembling transfer RNA but also containing radioactive phosphorus -- and mixed them with reverse transcriptase, Wilson says. The researchers then chopped the enzyme into small pieces and scanned the pieces. They discovered that a 100-amino-acid-long section near the center of the 560-amino-acid-long enzyme had latched onto the probe.

"Now we'll be able to focus on this small domain," Wilson says.

The investigators also studied the formation and stability of the RNA-enzyme complex in solutions with increasing concentrations of salt. From those studies, they concluded that the enzyme's docking site for transfer RNA consists of a groove with hydrophobic (water-repelling) protuberances as well as charged sections along the indentation. "That tells us to think in terms of developing hydrophobic compounds [to block the binding of RNA]," Wilson says.

In separate, unpublished work, molecular biologist Stuart F.J. Le Grice of Case Western Reserve University in Cleveland has identified the binding region as a smaller stretch of amino acids in the same part of the enzyme. Le Grice contends, however, that the form of the enzyme used by the NCI-Temple researchers was not the "biologically relevant" form that is active in the cell, and he expresses concern that some of the materials they used may not have been as pure as they thought.

"I doubt that the work is wrong," Le Grice says. But he thinks the story is more complicated than the new report suggests.
COPYRIGHT 1991 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Pennisi, Elizabeth
Publication:Science News
Date:Nov 23, 1991
Words:600
Previous Article:Suicidal ideas and coping in HIV-positives.
Next Article:Galileo snaps first close-up of an asteroid.
Topics:


Related Articles
AIDS studies suggest new directions, therapies.
What triggers AIDS?
AIDS meeting suggests basic research gaps.
Gout drug might cut AZT dosage by half.
AIDS: long research road still looms ahead.
AIDS: building a better inhibitor.
Shocking treatment proposed for AIDS.
AIDS update '96: new drugs, new tests, new optimism mark recent AIDS research.
Blood, semen harbor distinct HIV mutations.
Integrase inhibitors: first clear success in human trial.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters